» Articles » PMID: 26362269

IL-1β Produced by Aggressive Breast Cancer Cells is One of the Factors That Dictate Their Interactions with Mesenchymal Stem Cells Through Chemokine Production

Abstract

The aim of this work was to understand whether the nature of breast cancer cells could modify the nature of the dialog of mesenchymal stem cells (MSCs) with cancer cells. By treating MSCs with the conditioned medium of metastatic Estrogen-receptor (ER)-negative MDA-MB-231, or non-metastatic ER-positive MCF-7 breast cancer cells, we observed that a number of chemokines were produced at higher levels by MSCs treated with MDA-MB-231 conditioned medium (CM). MDA-MB-231 cells were able to induce NF-κB signaling in MSC cells. This was shown by the use of a NF-kB chemical inhibitor or an IκB dominant negative mutant, nuclear translocation of p65 and induction of NF-κB signature. Our results suggest that MDA-MB-231 cells exert their effects on MSCs through the secretion of IL-1β, that activates MSCs and induces the same chemokines as the MDA-MB-231CM. In addition, inhibition of IL-1β secretion in the MDA-MB-231 cells reduces the induced production of a panel of chemokines by MSCs, as well the motility of MDA-MB-231 cells. Our data suggest that aggressive breast cancer cells secrete IL-1β, which increases the production of chemokines by MSCs.

Citing Articles

IL-1β in Neoplastic Disease and the Role of Its Tumor-Derived Form in the Progression and Treatment of Metastatic Prostate Cancer.

Oyende Y, Taus L, Fatatis A Cancers (Basel). 2025; 17(2).

PMID: 39858071 PMC: 11763358. DOI: 10.3390/cancers17020290.


Partial Inhibition of Epithelial-to-Mesenchymal Transition (EMT) Phenotypes by Placenta-Derived DBMSCs in Human Breast Cancer Cell Lines, In Vitro.

Basmaeil Y, Subayyil A, Kulayb H, Kondkar A, Alrodayyan M, Khatlani T Cells. 2025; 13(24.

PMID: 39768220 PMC: 11674051. DOI: 10.3390/cells13242131.


Celecoxib inhibits NLRP1 inflammasome pathway in MDA-MB-231 Cells.

Arzuk E, Birim D, Armagan G Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(11):9191-9202.

PMID: 38990306 PMC: 11522188. DOI: 10.1007/s00210-024-03286-2.


The role of IL-1B in breast cancer bone metastasis.

Zhou J, Ottewell P J Bone Oncol. 2024; 46:100608.

PMID: 38800348 PMC: 11127524. DOI: 10.1016/j.jbo.2024.100608.


Development of an ultrasound-mediated nano-sized drug-delivery system for cancer treatment: from theory to experiment.

Moradi Kashkooli F, Jakhmola A, Ferrier G, Sathiyamoorthy K, Tavakkoli J, Kolios M Nanomedicine (Lond). 2024; 19(13):1167-1189.

PMID: 38722104 PMC: 11418290. DOI: 10.2217/nnm-2023-0259.


References
1.
Joyce J, Pollard J . Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009; 9(4):239-52. PMC: 3251309. DOI: 10.1038/nrc2618. View

2.
Dwyer R, Potter-Beirne S, Harrington K, Lowery A, Hennessy E, Murphy J . Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res. 2007; 13(17):5020-7. DOI: 10.1158/1078-0432.CCR-07-0731. View

3.
Chamberlain G, Wright K, Rot A, Ashton B, Middleton J . Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: comparison with human. PLoS One. 2008; 3(8):e2934. PMC: 2488395. DOI: 10.1371/journal.pone.0002934. View

4.
Ren G, Zhao X, Wang Y, Zhang X, Chen X, Xu C . CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell Stem Cell. 2012; 11(6):812-24. PMC: 3518598. DOI: 10.1016/j.stem.2012.08.013. View

5.
Kidd S, Spaeth E, Watson K, Burks J, Lu H, Klopp A . Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One. 2012; 7(2):e30563. PMC: 3282707. DOI: 10.1371/journal.pone.0030563. View